Cargando…

Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design

The cellular cytoskeleton forms the primary basis through which a cell governs the changes in size, shape, migration, proliferation, and forms the primary means through which the cells respond to their environment. Indeed, cell and tissue morphologies are used routinely not only to grade tumors but...

Descripción completa

Detalles Bibliográficos
Autores principales: Masoumi, Samaneh, Harisankar, Aditya, Gracias, Aileen, Bachinger, Fabian, Fufa, Temesgen, Chandrasekar, Gayathri, Gaunitz, Frank, Walfridsson, Julian, Kitambi, Satish S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026218/
https://www.ncbi.nlm.nih.gov/pubmed/27672311
http://dx.doi.org/10.2147/DDDT.S106196
_version_ 1782454096958062592
author Masoumi, Samaneh
Harisankar, Aditya
Gracias, Aileen
Bachinger, Fabian
Fufa, Temesgen
Chandrasekar, Gayathri
Gaunitz, Frank
Walfridsson, Julian
Kitambi, Satish S
author_facet Masoumi, Samaneh
Harisankar, Aditya
Gracias, Aileen
Bachinger, Fabian
Fufa, Temesgen
Chandrasekar, Gayathri
Gaunitz, Frank
Walfridsson, Julian
Kitambi, Satish S
author_sort Masoumi, Samaneh
collection PubMed
description The cellular cytoskeleton forms the primary basis through which a cell governs the changes in size, shape, migration, proliferation, and forms the primary means through which the cells respond to their environment. Indeed, cell and tissue morphologies are used routinely not only to grade tumors but also in various high-content screening methods with an aim to identify new small molecules with therapeutic potential. This study examines the expression of various cytoskeleton regulators in glioblastoma multiforme (GBM). GBM is a very aggressive disease with a low life expectancy even after chemo- and radiotherapy. Cancer cells of GBM are notorious for their invasiveness, ability to develop resistance to chemo- and radiotherapy, and to form secondary site tumors. This study aims to gain insight into cytoskeleton regulators in GBM cells and to understand the effect of various oncology drugs, including temozolomide, on cytoskeleton regulators. We compare the expression of various cytoskeleton regulators in GBM-derived tumor and normal tissue, CD133-postive and -negative cells from GBM and neural cells, and GBM stem-like and differentiated cells. In addition, the correlation between the expression of cytoskeleton regulators with the clinical outcome was examined to identify genes associated with longer patient survival. This was followed by a small molecule screening with US Food and Drug Administration (FDA)-approved oncology drugs, and its effect on cellular cytoskeleton was compared to treatment with temozolomide. This study identifies various groups of cytoskeletal regulators that have an important effect on patient survival and tumor development. Importantly, this work highlights the advantage of using cytoskeleton regulators as biomarkers for assessing prognosis and treatment design for GBM.
format Online
Article
Text
id pubmed-5026218
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50262182016-09-26 Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design Masoumi, Samaneh Harisankar, Aditya Gracias, Aileen Bachinger, Fabian Fufa, Temesgen Chandrasekar, Gayathri Gaunitz, Frank Walfridsson, Julian Kitambi, Satish S Drug Des Devel Ther Original Research The cellular cytoskeleton forms the primary basis through which a cell governs the changes in size, shape, migration, proliferation, and forms the primary means through which the cells respond to their environment. Indeed, cell and tissue morphologies are used routinely not only to grade tumors but also in various high-content screening methods with an aim to identify new small molecules with therapeutic potential. This study examines the expression of various cytoskeleton regulators in glioblastoma multiforme (GBM). GBM is a very aggressive disease with a low life expectancy even after chemo- and radiotherapy. Cancer cells of GBM are notorious for their invasiveness, ability to develop resistance to chemo- and radiotherapy, and to form secondary site tumors. This study aims to gain insight into cytoskeleton regulators in GBM cells and to understand the effect of various oncology drugs, including temozolomide, on cytoskeleton regulators. We compare the expression of various cytoskeleton regulators in GBM-derived tumor and normal tissue, CD133-postive and -negative cells from GBM and neural cells, and GBM stem-like and differentiated cells. In addition, the correlation between the expression of cytoskeleton regulators with the clinical outcome was examined to identify genes associated with longer patient survival. This was followed by a small molecule screening with US Food and Drug Administration (FDA)-approved oncology drugs, and its effect on cellular cytoskeleton was compared to treatment with temozolomide. This study identifies various groups of cytoskeletal regulators that have an important effect on patient survival and tumor development. Importantly, this work highlights the advantage of using cytoskeleton regulators as biomarkers for assessing prognosis and treatment design for GBM. Dove Medical Press 2016-09-12 /pmc/articles/PMC5026218/ /pubmed/27672311 http://dx.doi.org/10.2147/DDDT.S106196 Text en © 2016 Masoumi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Masoumi, Samaneh
Harisankar, Aditya
Gracias, Aileen
Bachinger, Fabian
Fufa, Temesgen
Chandrasekar, Gayathri
Gaunitz, Frank
Walfridsson, Julian
Kitambi, Satish S
Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
title Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
title_full Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
title_fullStr Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
title_full_unstemmed Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
title_short Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
title_sort understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026218/
https://www.ncbi.nlm.nih.gov/pubmed/27672311
http://dx.doi.org/10.2147/DDDT.S106196
work_keys_str_mv AT masoumisamaneh understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT harisankaraditya understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT graciasaileen understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT bachingerfabian understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT fufatemesgen understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT chandrasekargayathri understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT gaunitzfrank understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT walfridssonjulian understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign
AT kitambisatishs understandingcytoskeletonregulatorsinglioblastomamultiformefortherapydesign